Acadia Q3 revenue $278.6M (+11% YoY); net income $71.8M; raises FY 2025 guidance

ACADIA PHARMACEUTICALS INC

2025-Q3 EPS reported $0.69 revenue$787,516,000

Q3 net product sales: NUPLAZID $177.5M (+12% YoY), DAYBUE $101.1M (+11% YoY).
Q3 net income $71.8M ($0.42 diluted EPS) vs. $32.8M ($0.20) in Q3 2024.
Full-year 2025 total revenue guidance raised to $1.07-1.095B from $1.045-1.095B.
NUPLAZID guidance raised to $685-695M; DAYBUE guidance tightened to $385-400M.
Cash & investments $847M at Sept 30, 2025 vs. $756M at Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.